Bioharvest in vitro testing shows proprietary olive cell compound reduces fat accumulation in liver cells

Non-alcoholic fatty liver disease (nafld) affects 30-40% of u.s. adults, driving significant market need for bioharvest's future olive cell product targeting liver health vancouver, british columbia and rehovot, israel--(newsfile corp. - march 4, 2025) - bioharvest sciences inc.  (nasdaq: bhst) (fse: 8mv0) ("bioharvest" or "the company"), a company pioneering its patented botanical synthesis technology process, today announced new 'in vitro' test results for the company's proprietary new olive cell compound, which showed reduced fat accumulation in human liver cells. fat accumulation in the liver is a leading cause of non-alcohol fatty liver disease (nafld), which affects 30-40% of u.s. adults*.
BHST Ratings Summary
BHST Quant Ranking